ATE401404T1 - Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie - Google Patents

Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie

Info

Publication number
ATE401404T1
ATE401404T1 AT97952609T AT97952609T ATE401404T1 AT E401404 T1 ATE401404 T1 AT E401404T1 AT 97952609 T AT97952609 T AT 97952609T AT 97952609 T AT97952609 T AT 97952609T AT E401404 T1 ATE401404 T1 AT E401404T1
Authority
AT
Austria
Prior art keywords
ligand
kappa
receptor activator
tnf superfamily
receptors
Prior art date
Application number
AT97952609T
Other languages
English (en)
Inventor
Dirk Anderson
Laurent Galibert
Eugene Maraskovsky
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE401404(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE401404T1 publication Critical patent/ATE401404T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97952609T 1996-12-23 1997-12-22 Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie ATE401404T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5997896P 1996-12-23 1996-12-23
US7718197P 1997-03-07 1997-03-07
US6467197P 1997-10-14 1997-10-14

Publications (1)

Publication Number Publication Date
ATE401404T1 true ATE401404T1 (de) 2008-08-15

Family

ID=27369779

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97952609T ATE401404T1 (de) 1996-12-23 1997-12-22 Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
AT97953438T ATE497001T1 (de) 1996-12-23 1997-12-22 Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97953438T ATE497001T1 (de) 1996-12-23 1997-12-22 Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie

Country Status (13)

Country Link
US (21) US6017729A (de)
EP (5) EP2003203A1 (de)
JP (7) JP2002509431A (de)
AT (2) ATE401404T1 (de)
AU (2) AU713473B2 (de)
CA (1) CA2274987C (de)
DE (4) DE69738841D1 (de)
DK (1) DK0951551T4 (de)
ES (1) ES2144386T5 (de)
IL (1) IL130492A (de)
LU (1) LU91758I2 (de)
PT (1) PT951551E (de)
WO (2) WO1998028426A2 (de)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050060764A1 (en) * 2003-09-17 2005-03-17 Susan Gregory Mouse model for bone metabolism
US6919434B1 (en) 1995-02-20 2005-07-19 Sankyo Co., Ltd. Monoclonal antibodies that bind OCIF
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6479254B2 (en) 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6495520B2 (en) 1996-03-22 2002-12-17 Human Genome Sciences, Inc. Apoptosis Inducing Molecule II and methods of use
WO1998025958A2 (en) * 1996-12-13 1998-06-18 Schering Corporation Mammalian cell surface antigens comprising structural motifs characteristic of a member of the tnf ligand family
EP2003203A1 (de) 1996-12-23 2008-12-17 Immunex Corporation Ligand für den Rezeptorauslöser von NF-kappa b, wobei der Ligand Mitglied der TNF-Überfamilie ist
IL130491A (en) * 1996-12-23 2011-10-31 Immunex Corp Dna encoding rank polypeptide, the rank polypeptide and use thereof
AU2008200700C1 (en) * 1997-04-15 2013-04-04 Daiichi Sankyo Co., Ltd Novel Protein and Process for Producing The Same
EP2336168A1 (de) * 1997-04-15 2011-06-22 Sankyo Company Limited Neues Protein und Methoe zur Herstellung
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ATE363533T1 (de) * 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
CN1183159C (zh) 1997-09-24 2005-01-05 三共株式会社 破骨细胞形成抑制因子单克隆抗体、其用途和试剂盒
US7063960B2 (en) 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
WO1999029865A2 (en) * 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
US7019119B2 (en) 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
ATE412746T1 (de) 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
SI1114166T1 (en) * 1998-09-15 2005-10-31 Pharmexa A/S Method for down-regulating osteoprotegerin ligand activity
CN1318105A (zh) 1998-09-15 2001-10-17 M&E生物技术公司 负调节Osteoprotegerin配体活性的方法
IL145676A0 (en) 1999-04-12 2002-06-30 Genentech Inc Tumor necrosis factor homologs and nucleic acids encoding the same
US6492124B1 (en) 1999-06-11 2002-12-10 The Rockefeller University Trance activated signal transduction pathways in osteoclasts
US6872806B1 (en) * 1999-06-25 2005-03-29 The Governors Of The University Of Alberta Polypeptide compositions formed using a coiled-coil template and methods of use
ES2392392T3 (es) 1999-06-28 2012-12-10 Genentech, Inc. Métodos para producir ligando Apo-2 utilizando iones metálicos divalentes
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
ATE448781T1 (de) * 1999-07-28 2009-12-15 Univ Pennsylvania Methoden zur hemmung der aktivität der osteoklasten
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US6171860B1 (en) 1999-11-05 2001-01-09 Isis Pharmaceuticals, Inc. Antisense inhibition of rank expression
WO2001036637A1 (en) * 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
JP5062606B2 (ja) 2000-02-16 2012-10-31 ジェネンテック， インコーポレイテッド Ｔｎｆ関連分子の活性を調節するためのアゴニスト及びアンタゴニストの使用
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
DE60134459D1 (de) † 2000-02-23 2008-07-31 Amgen Inc Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
WO2001091793A1 (en) * 2000-05-26 2001-12-06 Smithkline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002009755A2 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
US20040247596A1 (en) * 2000-08-18 2004-12-09 Odgren Paul R. TRANCE regulation of chondrocyte differentiation
AU2001288342A1 (en) * 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002024896A2 (en) * 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US20040132971A1 (en) * 2001-02-09 2004-07-08 Haaning Jesper Mortensen Rank ligand-binding polypeptides
WO2002064782A2 (en) * 2001-02-09 2002-08-22 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
US20030013651A1 (en) * 2001-03-22 2003-01-16 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
EA200301041A1 (ru) * 2001-03-22 2004-08-26 Барнс-Джуиш Хоспитал Стимуляция остеогенеза с использованием гибридных белков лиганда для rank
CN1509328A (zh) * 2001-03-23 2004-06-30 Opg配体调节免疫应答的作用
WO2002092623A1 (en) * 2001-05-11 2002-11-21 Research Development Foundation INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF
US20040167072A1 (en) * 2001-05-11 2004-08-26 Aggarwal Bharat B. Inhibitors of receptor activator of NF-kappaB and uses thereof
EP1399175A4 (de) * 2001-05-17 2005-11-30 Immunex Corp Therapeutische verwendung von rang-antagonisten
US20040213788A1 (en) * 2001-05-18 2004-10-28 Sweet Raymond W. Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
MXPA03011270A (es) * 2001-06-06 2004-03-18 Immunex Corp Uso de antagonistas rank para tratar cancer.
EP1414517A4 (de) * 2001-06-26 2008-02-06 Photomed Technologies Inc Mehrfach-wellenlängen-illuminator
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
CA2451680C (en) 2001-07-03 2011-04-19 Genentech, Inc. Human dr4 antibodies and uses thereof
US20030050223A1 (en) * 2001-08-09 2003-03-13 Jonathan Lam Crystal forms and mutants of RANK ligand
CA2461292A1 (en) 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof
EP1442297A4 (de) * 2001-10-12 2004-12-15 Barnes Jewish Hospital Verfahren zur durchmusterung von osteogenen verbindungen
US20030100068A1 (en) * 2001-10-12 2003-05-29 Jonathan Lam RANKL mimics and uses thereof
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
EP1444341A2 (de) * 2001-10-15 2004-08-11 Barnes-Jewish Hospital Rankl imitierende substanzen und deren verwendungen
DE60237841D1 (de) 2001-11-13 2010-11-11 Genentech Inc Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US20030166559A1 (en) * 2002-01-04 2003-09-04 Desjarlais John R. Dominant negative proteins and methods thereof
US20040170602A1 (en) * 2002-01-04 2004-09-02 Desjarlais John R. Dominant negative proteins and methods thereof
WO2003059281A2 (en) * 2002-01-04 2003-07-24 Xencor Novel variants of rankl protein
US7381792B2 (en) * 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
WO2003080671A1 (en) * 2002-03-21 2003-10-02 Komed Co., Ltd. Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
PL375041A1 (en) * 2002-04-05 2005-11-14 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
JP4574350B2 (ja) 2002-06-24 2010-11-04 ジェネンテック， インコーポレイテッド Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
US20040138162A1 (en) * 2002-08-30 2004-07-15 Roodman G. David Method of resisting osteoclast formation
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
MXPA05006147A (es) * 2002-12-10 2005-08-26 Schering Plough Ltd Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
DE602004026157D1 (de) * 2003-01-10 2010-05-06 Protein Crystal Co Ltd Proteinkomplex, verfahren zu dessen herstellung und verwendung davon
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005028633A2 (en) * 2003-09-17 2005-03-31 Isis Pharmaceuticals, Inc. Modulation of rankl expression
US7252833B2 (en) * 2003-11-18 2007-08-07 Skeletal Kinetics, Llc Calcium phosphate cements comprising an osteoclastogenic agent
US7704686B2 (en) * 2003-12-29 2010-04-27 Toudai Tlo, Ltd. Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof
SG151294A1 (en) 2004-03-23 2009-04-30 Biogen Idec Inc Receptor coupling agents and therapeutic uses thereof
EP2412816B1 (de) 2004-07-26 2014-12-03 Pfenex Inc. Verfahren zur verbesserten Proteinexpression durch Strain-Engineering
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
CA2575152A1 (en) 2004-08-06 2006-02-16 Genentech, Inc. Method for predicting sensitivity of mammalian cells to apo2l/trail comprising deletion of biomarker expression
RU2410438C2 (ru) 2004-08-06 2011-01-27 Дженентек, Инк. Анализы и способы, использующие биомаркеры
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
RU2007119989A (ru) * 2004-12-02 2009-01-10 Домантис Лимитед (Gb) Композиции, слитые конструкции и конъюгаты plad домена
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
RU2409817C2 (ru) 2005-08-16 2011-01-20 Дженентек, Инк. Анализы и способы применения биомаркеров
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
EP1854458A1 (de) * 2006-05-08 2007-11-14 IMBA-Institut für Molekulare Biotechnologie GmbH Verwendung einer Verbindung mit RANKL Aktivität
JP5210156B2 (ja) 2006-05-12 2013-06-12 学校法人慶應義塾 炎症性疾患の検出並びに炎症性疾患の予防又は治療用組成物
WO2008044379A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
WO2008044797A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
CA2666415C (en) 2006-10-11 2012-11-27 Oriental Yeast Co., Ltd. Agent containing fused protein of soluble rankl with epitope tag
EP2615172A1 (de) 2007-04-27 2013-07-17 Pfenex Inc. Schnellscreeningverfahren für Bakterienwirte zur Identifizierung bestimmter Stämme mit verbessertem Ertrag und/oder verbesserter Qualität bei der Expression heterologer Proteine
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP5191487B2 (ja) 2007-06-05 2013-05-08 オリエンタル酵母工業株式会社 新しい骨量増加薬
CN101932935A (zh) * 2007-06-20 2010-12-29 先灵公司 用于炎性关节病抗白介素-17a治疗的关节破坏生物标记
MX2010001918A (es) 2007-08-21 2010-03-11 Amgen Inc Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino.
KR100911852B1 (ko) 2007-11-26 2009-08-11 고려대학교 산학협력단 유세포 분석기를 이용한 신규한 ｒａｎｋ와 ｒａｎｋ리간드의 결합 분석방법
WO2009105934A1 (zh) * 2008-02-27 2009-09-03 上海先导药业有限公司 抗人rankl单克隆抗体
AR073072A1 (es) 2008-08-19 2010-10-13 Regeneron Pharma Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
US8657662B2 (en) 2008-09-04 2014-02-25 Patent Investment & Licensing Company Gaming device having variable speed of play
US9435811B2 (en) 2008-09-30 2016-09-06 Oriental Yeast Co., Ltd Inducer of chondrocyte proliferation and differentiation
CN101712964B (zh) * 2008-10-08 2013-05-08 上海科新生物技术股份有限公司 抑制破骨细胞形成的融合蛋白、其制备方法及药物组合物
MX2011005481A (es) 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
CN101514232B (zh) * 2009-03-25 2013-06-19 上海科新生物技术股份有限公司 一种RANKL-Fc融合蛋白及其制备方法和用途
US9079957B2 (en) 2009-04-16 2015-07-14 The University Of Tokyo Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
KR101153393B1 (ko) * 2009-09-21 2012-06-07 고려대학교 산학협력단 점변이 이용한 수용성 재조합 인간 ｒａｎｋ의 효능 향상 및 골 질환 치료용 조성물
EP3372617B1 (de) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Bindungsfusionsproteine, bindungsfusionsproteinarzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zur herstellung und verwendung davon
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
EP2433644A1 (de) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Brustkrebstherapeutika
EP2434285A1 (de) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Brustkrebsdiagnose
DK3091085T3 (da) 2010-10-06 2019-05-06 Inst Catalana Recerca Estudis Avancats Fremgangsmåde til at designe en terapi mod brystcancermetastase
EP2692359B1 (de) 2011-03-31 2017-06-07 Oriental Yeast Co., Ltd. Krebsimmunitätsverstärker mit einem rankl-antagonisten
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
FR2980711A1 (fr) * 2011-10-03 2013-04-05 Centre Nat Rech Scient Modulation du systeme immunitaire et des cellules stromales via rank
EP2776066B1 (de) 2011-11-07 2018-09-19 Universite Laval Rank-/rankl-antagonisten zur verwendung zur behandlung neuromuskulärer erkrankungen, genetischer myopathien und/oder nicht genetischer myopathien
EP2650682A1 (de) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Asymmetrische Ester von als Schmiermittel geeigneten Fettsäuren
EP3467124A1 (de) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Verfahren zur diagnose, prognose und behandlung von lungenkrebsmetastasen
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
JP6074049B2 (ja) 2012-10-12 2017-02-01 インバイオモーション エセ．エレ． ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
AU2014229505B2 (en) 2013-03-15 2020-02-27 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
CA2920376A1 (en) 2013-08-07 2015-02-12 Martin Blomberg JENSEN Methods and composition comprising denosumab or an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a rankl/opgbp peptide for use in the treatment, prevention or alleviation of male infertility
WO2015030701A1 (en) * 2013-08-24 2015-03-05 R-Pharm Overseas, Inc. Fully human antibodies against human rankl
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP6550045B2 (ja) 2013-10-09 2019-07-24 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） 乳がんに由来する骨の転移がんの予後診断および処置のための方法
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
EP4035664A3 (de) 2014-03-28 2022-11-30 Duke University Behandlung von krebs unter verwendung von selektiven östrogenrezeptormodulatoren
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
CN104829725A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd133×cd3的构建及应用
MX393599B (es) 2015-04-29 2025-03-19 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
ES2755031T3 (es) 2015-05-18 2020-04-21 Lilly Co Eli Compuestos de anticuerpos biespecíficos ANTI-DKK-1-ANTI-RANKL
EP3299382B1 (de) * 2015-05-20 2023-04-26 Osaka University Oligopeptid mit proinflammatorischer zytokinsekretionshemmender wirkung
EP3400003B1 (de) * 2016-01-05 2023-05-03 The Trustees of Columbia University in the City of New York Zusammensetzungen zur regulierung der aktivität des inhibitors des dna-binding-2 (id2)-proteins
WO2017123642A1 (en) * 2016-01-12 2017-07-20 The Trustees Of The University Of Pennsylvania Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis
EP3411066A1 (de) 2016-02-01 2018-12-12 Eli Lilly and Company Parathormon-anti-rankl-antikörperfusionsverbindungen
WO2017156058A1 (en) 2016-03-08 2017-09-14 Janssen Biotech, Inc. Gitr antibodies, methods, and uses
PT3458610T (pt) 2016-05-25 2021-06-29 Inbiomotion Sl Tratamento terapêutico de cancro da mama baseado no estado de c-maf
AU2017294772B2 (en) 2016-07-14 2024-05-02 Scholar Rock, Inc. TGFB antibodies, methods, and uses
CN109890845B (zh) 2016-10-28 2022-07-01 伊莱利利公司 抗rankl抗体及其用途
DK3565542T3 (da) 2017-01-05 2024-07-01 Radius Pharmaceuticals Inc Polymorphic forms of rad1901-2hcl
JP7672196B2 (ja) 2017-03-14 2025-05-07 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
WO2019102380A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
KR102792490B1 (ko) 2018-07-04 2025-04-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
US11499928B2 (en) * 2018-08-24 2022-11-15 University Of Wyoming Methods and systems for isochoric measurements using differential scanning calorimetry
WO2020070288A1 (en) 2018-10-05 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
EP3883610A4 (de) 2018-11-20 2022-11-02 Cornell University Makrocyclische komplexe von radionukliden und deren verwendung in der radiotherapie von krebs
MX2021009569A (es) 2019-02-12 2021-09-08 Radius Pharmaceuticals Inc Procesos y compuestos.
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
EP4110371A1 (de) 2020-01-24 2023-01-04 Radius Health, Inc. Verfahren zur stimulierung des knochenwachstums mit abalopartid und denosumab
CN111793135A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中rankl含量的抗体对及其用途
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023179791A1 (en) * 2022-03-24 2023-09-28 Angitia Biomedicines Limited Treatment of musculoskeletal disorders
EP4507779A1 (de) 2022-04-14 2025-02-19 Institut National de la Santé et de la Recherche Médicale Verfahren zur kontrolle der tumorzellabtötung durch licht
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
WO1986000922A1 (en) 1984-07-30 1986-02-13 The Salk Institute For Biological Studies Retroviral gene transfer vectors
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US6150090A (en) * 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US5116952A (en) * 1986-07-18 1992-05-26 The University Of Melbourne Protein active in humoral hypercalcemia of malignancy-pthrp
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
CA2071912C (en) * 1990-11-30 2002-10-15 Hanne Bentz Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair
US6121002A (en) * 1990-12-26 2000-09-19 The Rowett Research Institute Method to detect bone and other connective tissue disorders in humans and animals
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) * 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
DE69233051T2 (de) * 1991-10-25 2004-03-11 Immunex Corp., Seattle Antikörper gegen CD40-L
EP0746609A4 (de) 1991-12-17 1997-12-17 Genpharm Int Heterologe antikörper produzierende transgene nicht-humane tiere
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JPH07509223A (ja) 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5578569A (en) * 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
JPH09502614A (ja) * 1993-09-14 1997-03-18 メルク エンド カンパニー インコーポレーテッド 新規ヒト蛋白質チロシンホスファターゼをコードするｃＤＮＡ
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
EP0727211A1 (de) 1995-02-10 1996-08-21 Smithkline Beecham Corporation Verwendung von src SH2-spezifische Verbindungen zur Behandlung von Knochenresorptionserkrankungen
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7094564B1 (en) * 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US20030166097A1 (en) * 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
EP0822984A4 (de) * 1995-04-27 2000-05-03 Human Genome Sciences Inc Rezeptor für humanen tumor nekrosis faktor
AU693713B2 (en) 1995-06-07 1998-07-02 Immunex Corporation CD40L mutein
AU6090896A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
WO1997000317A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
ES2253753T3 (es) * 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
ZA966663B (en) 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
JPH0997808A (ja) 1995-09-29 1997-04-08 Mitsumi Electric Co Ltd ダイボンディング装置
JPH09151434A (ja) 1995-11-24 1997-06-10 Tootetsu:Kk 角形蛇籠の変形防止枠及びその蛇籠の設置方法
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
PT873405E (pt) 1996-01-11 2005-01-31 Immunex Corp Elementos de sequencia que aumentam a expressao (ease) para sistemas de expressao eucarioticos
JPH09217897A (ja) 1996-02-14 1997-08-19 Hitachi Ltd Ｓｆ６貯蔵供給装置、その貯蔵方法及び供給方法
JPH09224803A (ja) 1996-02-21 1997-09-02 Nakajima Cafe Honsha:Kk 蓋付きコーヒーカップ
US5766223A (en) 1996-03-21 1998-06-16 Johnson; Deborah M. Child's teething device
US5710013A (en) 1996-04-19 1998-01-20 Tularik Inc. Tumor necrosis factor receptor associated factor 6 (TRAF6)
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
WO1998025958A2 (en) * 1996-12-13 1998-06-18 Schering Corporation Mammalian cell surface antigens comprising structural motifs characteristic of a member of the tnf ligand family
WO1998028423A2 (en) * 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
EP2003203A1 (de) * 1996-12-23 2008-12-17 Immunex Corporation Ligand für den Rezeptorauslöser von NF-kappa b, wobei der Ligand Mitglied der TNF-Überfamilie ist
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
EP2336168A1 (de) 1997-04-15 2011-06-22 Sankyo Company Limited Neues Protein und Methoe zur Herstellung
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ATE363533T1 (de) * 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
JP2002514079A (ja) 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド キメラｏｐｇポリペプチド
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US7063960B2 (en) 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
US7019119B2 (en) 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
JPH11266872A (ja) * 1998-03-20 1999-10-05 Suntory Ltd ＮＦ−κＢの活性化を抑制する物質のスクリーニング方法
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
ATE412746T1 (de) 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
HUP0102492A2 (hu) 1998-06-19 2001-11-28 Smithkline Beecham Corp. Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
US6252180B1 (en) * 1999-08-09 2001-06-26 Lucent Technologies Inc. Electromagnetic interference cover for a conduit and an electronic equipment chassis employing the same
CA2349406C (en) 1999-09-03 2011-01-11 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
DE60134459D1 (de) 2000-02-23 2008-07-31 Amgen Inc Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
AU2001288342A1 (en) * 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
MY143582A (en) * 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
PL375041A1 (en) 2002-04-05 2005-11-14 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US7157993B2 (en) 2003-09-30 2007-01-02 Rockwell Scientific Licensing, Llc 1:N MEM switch module

Also Published As

Publication number Publication date
US6649164B2 (en) 2003-11-18
LU91758I9 (de) 2019-01-02
US8153775B2 (en) 2012-04-10
ES2144386T9 (es) 2013-02-18
JP4054354B2 (ja) 2008-02-27
JP4203105B2 (ja) 2008-12-24
EP0951551A2 (de) 1999-10-27
US7932375B2 (en) 2011-04-26
US6562948B2 (en) 2003-05-13
US8333963B2 (en) 2012-12-18
IL130492A0 (en) 2000-06-01
US6740522B2 (en) 2004-05-25
EP2314695A3 (de) 2011-12-21
DK0951551T4 (da) 2012-09-10
US20110086033A1 (en) 2011-04-14
US20050003391A1 (en) 2005-01-06
US20080009014A1 (en) 2008-01-10
US20140186887A1 (en) 2014-07-03
JP2010241823A (ja) 2010-10-28
US7411050B2 (en) 2008-08-12
US6838262B1 (en) 2005-01-04
AU713471B2 (en) 1999-12-02
US20020086826A1 (en) 2002-07-04
DK0951551T3 (da) 2008-09-01
EP0951551B1 (de) 2008-07-16
LU91758I2 (fr) 2011-01-24
DE951551T1 (de) 2000-09-14
US6479635B1 (en) 2002-11-12
ES2144386T1 (es) 2000-06-16
DE69740107D1 (de) 2011-03-10
EP2371962A2 (de) 2011-10-05
US6017729A (en) 2000-01-25
EP0951551B9 (de) 2012-12-26
US20140235832A1 (en) 2014-08-21
US8715683B2 (en) 2014-05-06
IL130492A (en) 2007-09-20
US20030175840A1 (en) 2003-09-18
US20120178912A1 (en) 2012-07-12
PT951551E (pt) 2008-10-28
US8569456B2 (en) 2013-10-29
US20020081720A1 (en) 2002-06-27
CA2274987A1 (en) 1998-07-02
AU5718498A (en) 1998-07-17
JP2002509431A (ja) 2002-03-26
DE122010000048I1 (de) 2011-05-05
JP2007014339A (ja) 2007-01-25
EP0946725A2 (de) 1999-10-06
WO1998028424A2 (en) 1998-07-02
AU5618098A (en) 1998-07-17
US20110200990A1 (en) 2011-08-18
US7744886B2 (en) 2010-06-29
AU713473B2 (en) 1999-12-02
JP4242913B2 (ja) 2009-03-25
CA2274987C (en) 2012-01-24
ES2144386T3 (es) 2009-01-16
US20130203682A1 (en) 2013-08-08
ATE497001T1 (de) 2011-02-15
JP2008133302A (ja) 2008-06-12
JP2002509430A (ja) 2002-03-26
EP2371962A3 (de) 2011-12-21
DE69738841D1 (de) 2008-08-28
US20120034690A1 (en) 2012-02-09
US20090017033A1 (en) 2009-01-15
US7262274B2 (en) 2007-08-28
EP0951551B2 (de) 2012-08-08
AU713471C (en) 2002-04-18
JP5096527B2 (ja) 2012-12-12
JP2009051862A (ja) 2009-03-12
US20020169117A1 (en) 2002-11-14
ES2144386T5 (es) 2012-12-07
US6528482B1 (en) 2003-03-04
US8377690B2 (en) 2013-02-19
US6242213B1 (en) 2001-06-05
US20020086827A1 (en) 2002-07-04
EP0946725B1 (de) 2011-01-26
JP4138013B2 (ja) 2008-08-20
US6537763B2 (en) 2003-03-25
US6419929B1 (en) 2002-07-16
WO1998028424A3 (en) 1998-09-11
JP2008113656A (ja) 2008-05-22
EP2314695A2 (de) 2011-04-27
WO1998028426A2 (en) 1998-07-02
EP2003203A1 (de) 2008-12-17

Similar Documents

Publication Publication Date Title
ATE401404T1 (de) Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
ATE187982T1 (de) Cytokine antagoniste
DE69633617D1 (de) Il-17 receptor
FI946005L (fi) Glysiinireseptoriantagonisteja ja niiden käyttö
ATE309375T1 (de) Onkostatin- m rezeptor
FR2569666B1 (fr) Dispositif permettant de conserver, separes l'un de l'autre, au moins deux produits et d'effectuer leur melange ulterieurement, notamment au moment de l'utilisation
EP0667773A4 (de) Fibrinogen-rezeptor-antagonisten.
FI933810L (fi) Reseptorantagonister av exiterbara aminosyror
ATE114724T1 (de) Antikörper gegen tnf-bindungsprotein i und deren f(ab)-fragmente.
DE69207351D1 (de) Fibrinogen-Rezeptor-Antagoniste
FI934894A7 (fi) Fibrinogeenireseptorin antagonisteja
DE69032963D1 (de) (Modifiziertes) hydriertes Dien-Blockcopolymer und dieses enthaltende Zusammensetzung
IT1228211B (it) Agglomerato combustibile resistente all'acqua, procedimento per la sua preparazione e composizione di materiali usata in tale procedimento.
DK0842132T3 (da) På vand flydende partikelformige materialer, der indeholder mikronæringsstoffer til fytoplankton
FR2695475B1 (fr) Conductivimètre pour mesurer en régime transitoire la conductivité d'un matériau injectable ou non.
TR28355A (tr) Hidrolik cimento "BUGHOLE" (bosluk) sayisini azaltici ilave karisimlar ve bunlarin kullanimi ile ilgili yöntem.
IL99501A0 (en) Interleukin 9 receptors,methods for the use thereof and pharmaceutical compositions containing the same
EP0928419A4 (de) Zusammensetzungen und verfahren zur regulierung der expression des type-i-interleukin-1-rezeptors
NO179550C (no) Tachykinin reseptorantagonister
IT8948295A0 (it) Procedimento ed apparecchio per la cernita di materiali particellari mediante attrito
DE58907320D1 (de) Bituminöse Masse und deren Verwendung.
DE69230659D1 (de) Polypeptide, die an die schweren Ketten von IL-2-Rezeptoren binden können
DE69003364D1 (de) Einrichtung zum Einfahren von Gewindeverbindungen für Rohrstränge durch Festschrauben und Losdrehen.
IT8884948A0 (it) Dispositivo posacanna per il rilevamento automatico dell'abboccamento all'amo.
IT1161553B (it) Materiali minerali granulari stabilizzati per impieghi in mantichiari e riflettenti per strade,piste e simili,e procedimento per ottenerli